Researchers sought to determine whether CD19-targeting CAR-T therapy would be an effective therapy for patients with relapsed/refractory LBCL.

Researchers use targeted lipid nanoparticles loaded with mRNA to reprogram T cells to fight autoimmune diseases ...

Although the mother and her breastmilk tested positive for CAR T cells, the baby did not, showing only normal T- and B-cell subsets.

"ALA-CART improves the ability of CAR-T cells to detect and attack resistant cancer cells more effectively. This could lead ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international Phase I/II clinical trial led ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without ...

After a single dose of equecabtagene autoleucel, three people with progressive MS saw benefits, including improved walking ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: CAR-T Cell Therapy for ALL ...

Therapy is one of the most revolutionary advancements in oncology, offering a personalized immunotherapy approach that ...

Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...

Using human T cells and leukemia cells in specialized mouse models, researchers developed the novel ALA-CART cells which showed promising results in fighting acute lymphocytic leukemias that were ...